Holen Sie sich die Stockscreener-App
3.085
3.10%
-0.095
Schlusskurs vom Vortag:
$3.18
Offen:
$3.09
24-Stunden-Volumen:
54,424
Relative Volume:
0.08
Marktkapitalisierung:
$454.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-13.73
EPS:
-0.2247
Netto-Cashflow:
-
1W Leistung:
+9.66%
1M Leistung:
-1.55%
6M Leistung:
+79.16%
1J Leistung:
+58.84%
1-Tages-Spanne:
$3.07
$3.15
1-Wochen-Bereich:
$2.74
$3.23
52-Wochen-Spanne:
$1.32
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Firmenname
Immutep Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IMMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
3.085 | 468.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.77 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.30 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-17 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-07-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-09-28 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Immutep Limited Adr Aktie (IMMP) Neueste Nachrichten
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Immutep reports positive phase I data for first-in-class autoimmune antibody IMP761 - MSN
Why Immutep Limited (Common Stock) (YP1A) stock is trending on social mediaHealthcare Stock Analysis & Investment Portfolio Recommendations - Bollywood Helpline
Immutep (IMMP) reports positive IMP761 Phase I study update - Stock Titan
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely - Sahm
Will Immutep Limited Depositary Receipt stock see insider buying2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Why Immutep Limited (YP1B) stock is a strong analyst pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - Улправда
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Finviz
Ready to Jump After Recent Trade: Beta Bionics Inc (BBNX) - setenews.com
An analyst sees good growth prospects for Immutep Limited ADR (IMMP) - setenews.com
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep Gains FDA Support for Cancer Therapy Development - TipRanks
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data - Finviz
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep stock soars on promising trial results - Investing.com
Immutep Advances Cancer Trials with Promising Developments - TipRanks
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire
Immutep Limited (NASDAQ: IMMP)Share Price - intelligentinvestor.com.au
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
symbol__ Stock Quote Price and Forecast - CNN
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
IMMP Stock Price, Forecast & Analysis | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - Chartmill
Immutep Limited (ASX: IMM) - The Motley Fool Australia
Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown
Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news
Technical Analysis of Immutep Ltd Sponsored ADR (NASDAQ:IMMP) - TradingView
IMM Stock Price and Chart — ASX:IMM - TradingView — Track All Markets
IMMP - Finviz
IMMP Stock Price | Immutep Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView — Track All Markets
Finanzdaten der Immutep Limited Adr-Aktie (IMMP)
Es liegen keine Finanzdaten für Immutep Limited Adr (IMMP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):